Grifols (GRFS) Land & Improvements (2020 - 2021)
Grifols' (GRFS) quarterly Land & Improvements came in at $910.2 million in Q4 2021, up 12.48% YoY from $809.2 million in Q4 2020, and up 12.48% on a QoQ basis from $809.2 million in Q4 2020.
Grifols (GRFS) Land & Improvements (2020 - 2021) Analysis & Trends
Grifols (GRFS) has 2 years of Land & Improvements data on file, last reported at $910.2 million in Q4 2021.
- Quarterly Land & Improvements rose 12.48% year-over-year to $910.2 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $910.2 million (up 12.48% YoY) and the FY2021 annual result came in at $910.2 million, up 17.46% from the prior year.
- Land & Improvements advanced to $910.2 million in Q4 2021, from $809.2 million in the prior quarter.
- In the past five years, Land & Improvements ranged from a high of $910.2 million in Q4 2021 to a low of $809.2 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Land & Improvements (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 910.21 Mn |
| Dec 31, 2020 | 809.20 Mn |